Online citations, reference lists, and bibliographies.
← Back to Search

Comparing IncobotulinumtoxinA (Xeomin®) And OnabotulinumtoxinA (Botox®): Identical Potency Labelling In The Hemidiaphragm Assay

D. Dressler, Lizhen Pan, H. Bigalke
Published 2018 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Botulinum toxin (BT) is provided by several manufacturers producing a number of different drugs. Their potency is given in internationally standardised mouse units (MU). Clinical practise, however, reveals that the potency labelling of different BT drugs may not be identical. We wanted to use the mouse diaphragm assay (MDA) to compare the two BT drugs onabotulinumtoxinA (ONA) and incobotulinumtoxinA (INCO). For this, we measured the paresis time (PT) of different ONA or INCO doses. All BT came from several different and unexpired drug batches. PT for 20MU were 169.7 ± 28.9 min (ONA) and 132.3 ± 1.5 min (INCO) (p = 0.089), for 60MU 105.3 ± 10.1 min and 84.7 ± 4.2 min (p = 0.031), for 100MU 69.7 ± 1.5 min and 66.0 ± 7.0 min (p = 0.462) and for 140MU 74.7 ± 0.6 min and 62.3 ± 2.1 min (p = 0.100), respectively. The overall PT were 104.8 ± 12.5 and 86.3 ± 8.5 min (p = 0.178). Results presented here do not reveal differences in potency labelling between ONA and INCO, even when the full range of therapeutic doses are examined, although there was a trend towards stronger INCO effects. Data confirm previous reports on identical potency labelling of ONA and INCO. The MDA seems to be an appropriate instrument to test the potency labelling of other BT drugs as well, including new BT drugs currently under development.
This paper references
10.1016/J.TOXICON.2016.11.068
Comparing incobotulinumtoxina (Xeomin) and onabotulinumtoxina (Botox): Identical potency labeling in the hemidiaphragm assay
D. Dressler (2016)
10.1111/j.1476-5381.1997.tb06771.x
OBSERVATIONS ON THE ISOLATED PHRENIC NERVE DIAPHRAGM PREPARATION OF THE RAT
E. Bülbring (1997)
10.1111/j.1468-1331.2009.02877.x
Routine use of Xeomin® in patients previously treated with Botox®: long term results
D. Dressler (2009)
The medical geography of air pollution.
Russell Wm (1993)
10.3390/toxins8030065
Conversion Ratio between Botox®, Dysport®, and Xeomin® in Clinical Practice
F. Scaglione (2016)
10.1111/j.1468-1331.2011.03559.x
Five‐year experience with incobotulinumtoxinA (Xeomin®): the first botulinum toxin drug free of complexing proteins
D. Dressler (2012)
10.1002/mds.22336
Respective potencies of Botox® and Dysport® in a human skin model: A randomized, double‐blind study
G. Kranz (2009)
Dose standardisation of BTX
P Van den Bergh (1996)
10.1006/exnr.1997.6580
Botulinum A Toxin Therapy: Neutralizing and Nonneutralizing Antibodies—Therapeutic Consequences
H. Göschel (1997)
10.1097/WNF.0b013e3181692735
Potency Evaluation of a Formulated Drug Product Containing 150-kd Botulinum Neurotoxin Type A
Terrence Hunt (2009)
10.1007/s00702-010-0372-0
Comparing Botox® and Xeomin® for axillar hyperhidrosis
D. Dressler (2010)
10.1007/s00702-005-0323-3
Efficacy and safety of a new Botulinum Toxin Type A free of complexing proteins in the treatment of blepharospasm
P. Roggenkaemper (2005)
10.1007/s00702-011-0719-1
Measuring the potency labelling of onabotulinumtoxinA (Botox®) and incobotulinumtoxinA (Xeomin®) in an LD50 assay
D. Dressler (2011)
Medico-legal reports.
McCormack Mp (1993)
10.1212/01.WNL.0000163767.99354.C3
A new botulinum toxin type A free of complexing proteins for treatment of cervical dystonia
R. Benecke (2005)
10.1136/jnnp.59.1.102
Dose standardisation of botulinum toxin.
M. Marion (1995)
10.1007/s00702-013-1076-z
Botulinum toxin therapy of cervical dystonia: comparing onabotulinumtoxinA (Botox®) and incobotulinumtoxinA (Xeomin®)
D. Dressler (2013)
10.1006/TAAP.1994.1181
Measurement of botulinum toxin activity: evaluation of the lethality assay.
L. Pearce (1994)
10.1136/jnnp.72.4.430
Respective potencies of Botox and Dysport: a double blind, randomised, crossover study in cervical dystonia
W. Poewe (2002)
10.1111/j.1476-5381.1997.tb06770.x
Observations on the isolated phrenic nerve diaphragm preparation of the rat
E. B. and (2011)
10.1097/WNF.0B013E3181ACEFAF
Editorial Response Letter to Mander et al
Terrence Hunt (2009)
10.1007/s00415-009-5182-7
Biological activity of two botulinum toxin type A complexes (Dysport® and Botox®) in volunteers
K. Wohlfarth (2009)
Botulinum toxin: dangerous terminology errors.
I. Lorentz (1994)



This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar